• Oct 23, 2026

  $1,273.46-2.54%

  Eli Lilly closed down 2.54%, a larger drop than its peers. Comparable pharmaceutical companies moved -0.86% on average, with 4 of 6 falling and 2 rising [1]. The decline was therefore only partly shared by the group. The other items were an opinion piece and a piece about a different company, and neither reports an event.

  • 1Peer group

• Oct 22, 2026

  $1,306.69+2.83%

  Comparable pharmaceutical companies rose 1.35% on average, with 5 of 6 advancing [1]. LLY's gain of 2.83% was larger than the group average, though MRK fell 1.76% [1].

  • 1Peer group

• Oct 21, 2026

  $1,270.75-1.01%

• Oct 20, 2026

  $1,283.66+3.49%

  Comparable pharmaceutical companies rose 1.83% on average, with five of six higher, so the gain was partly shared by the group [1]. 24/7 Wall St reported that a European regulatory committee had handed Eli Lilly a potential edge in the obesity pill race as Foundayo neared European approval [2]. Seeking Alpha reported a deal with METiS TechBio on AI-driven drug delivery worth up to $1.1B [3], and also that the shares hit an all-time high [4].

  • 1Peer group
  • 224/7 Wall St
  • 3Seeking Alpha
  • 4Seeking Alpha

• Oct 19, 2026

  $1,240.34-1.33%

  Seeking Alpha reported that Lilly planned to seek an Omvoh label expansion for pediatric ulcerative colitis after positive Phase 3 SHINE-2 trial data [1]. The shares nonetheless closed down 1.33%, and the items hold no reported cause for the decline.

  • 1Seeking Alpha

• Oct 16, 2026

  $1,257.03+0.43%

  Shares rose 0.43% on a day when Seeking Alpha reported that Lilly won EU backing for its Foundayo weight-loss pill [1]. Seeking Alpha also noted Lilly was among the winners of EU drug recommendations this month [2]. No sector or market figures were supplied to show how the move compared with others.

  • 1Seeking Alpha
  • 2Seeking Alpha

• Oct 15, 2026

  $1,251.61+3.55%

  Comparable pharmaceutical companies rose 0.46% on average, so Lilly's larger gain was not matched by the group [1]. Seeking Alpha reported that Omvoh hit one-year remission goals in ulcerative colitis and Crohn's disease [2]. Lilly also confirmed it would announce third-quarter results on October 29, 2026 [3]. Volume was 1.6x its trailing average [4].

  • 1Peer group
  • 2Seeking Alpha
  • 3Pr Newswire
  • 4Market data

Closing prices for LLY. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.